Evidence map›Paper›PMID 41669110›Full record

ArticleFrontiers in oncology2026

Case Report: Prolonged response to cabozantinib and pembrolizumab in treatment-refractory metastatic pancreatic ductal adenocarcinoma.

Anna M Reagan, Hannah G McDonald, Jaewon Kang, Hoda Saghaeiannejad Esfahani, Caroline G Wright, Charles J Bailey, Carleton S Ellis, Kaylyn R Collette, Reema A Patel, Mayte Murillo and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anna M ReaganDepartment of Surgery, University of Kentucky, Lexington, KY, United States.
Hannah G McDonaldDepartment of Surgery, University of Kentucky, Lexington, KY, United States.
Jaewon KangUniversity of Kentucky School of Medicine, Lexington, KY, United States.
Hoda Saghaeiannejad EsfahaniDepartment of Surgery, University of Kentucky, Lexington, KY, United States.
Caroline G WrightDepartment of Surgery, University of Kentucky, Lexington, KY, United States.
Charles J BaileyDepartment of Surgery, University of Kentucky, Lexington, KY, United States.
Carleton S EllisCollege of Pharmacy, University of Kentucky, Lexington, KY, United States.
Kaylyn R ColletteCollege of Pharmacy, University of Kentucky, Lexington, KY, United States.
Reema A PatelMarkey Cancer Center, University of Kentucky, Lexington, KY, United States.
Mayte MurilloMarkey Cancer Center, University of Kentucky, Lexington, KY, United States.
Samantha F StokleyMarkey Cancer Center, University of Kentucky, Lexington, KY, United States.
Michael J CavnarDepartment of Surgery, University of Kentucky, Lexington, KY, United States.
Prakash K PandalaiDepartment of Surgery, University of Kentucky, Lexington, KY, United States.
Mautin T Barry-HundeyinDepartment of Surgery, University of Kentucky, Lexington, KY, United States.
Jessica J MossMarkey Cancer Center, University of Kentucky, Lexington, KY, United States.
Joseph KimDepartment of Surgery, University of Kentucky, Lexington, KY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has yet to demonstrate durable efficacy in pancreatic ductal adenocarcinoma (PDAC) despite the fact that pancreatic cancer cells have higher levels of immune checkpoint expression than other cancer cell types in which immunotherapy efficacy has been well established. We observed effective cytotoxicity with the combination therapy of pembrolizumab (an anti-PD-1 monoclonal antibody, mAb) and cabozantinib (an anti-MET small molecule)

Indexed as

cabozantinibcase reportosteoclast-like giant cellspancreatic cancerpembrolizumab

Identifiers

PMID41669110
PMCPMC12883355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.